Brief: Merck’S Tulisokibart Met Primary And Key Secondary Endpoints In The Phase 3 Atlas-Uc Induction-Only Study In Patients With Moderately To Severely Active Ulcerative Colitis (Uc)
22/06/2026 11:49
BRIEF-Merck’S Tulisokibart Met Primary And Key Secondary Endpoints In The Phase 3 Atlas-Uc Induction-Only Study In Patients With Moderately To Severely Active Ulcerative Colitis (Uc) June 22 (Reuters) - Merck & Co Inc MRK.N:
MERCK’S TULISOKIBART MET PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3 ATLAS-UC INDUCTION-ONLY STUDY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)
MERCK CO - NO SAFETY CONCERNS IDENTIFIED IN PHASE 3 ATLAS-UC STUDY OF TULISOKIBART
MERCK’S TULISOKIBART MET PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3 ATLAS-UC INDUCTION-ONLY STUDY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)
MERCK CO - TULISOKIBART FIRST ANTI-TL1A ANTIBODY TO SHOW CLINICAL REMISSION AT 12 WEEKS IN PHASE 3 UC TRIAL
Source text: ID:nBw6c8dfca
Further company coverage: MRK.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merck & Co
See all newsU.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin
Eli Lilly, Pfizer slip after US House panel probing China clinical trials
US House committee opens investigation into Merck, AbbVie China drug trials (updated)
Brief: U.S. House Committee Sends Letters To Pfizer, Eli Lilly & Bristol Myers Squibb Probing China Drug Trials